Sylvia McBrinn has significant executive management experience in the pharmaceutical and biotech industries. She currently serves on the board of BioAtla, a public oncology company. Ms. McBrinn was the founding CEO of ReNetX Bio (then Axerion Therapeutics) a private, an early stage Neurology focused biotech company. She has served on both the board of directors of ReNetX Bio and of Ilya Pharma (a private biotech company) and on the Advisory Board of Rebiotix, Inc (a microbiome focused company) prior to it's acquisition by Ferring. During the time Ms. McBrinn was CEO of ReNetX Bio, she raised seed and significant non-dilutive funding and secured a partnership with a major Pharmaceutical company for one of the company's key programs. She is a member of the Life Science Council for Springboard Enterprises, advising female entrepreneurs. From 2005 to 2008, Ms. McBrinn was the head of the US subsidiary of Vernalis, a British Biotech company where she was responsible for establishing and growing the commercial organization and selling the subsidiary to Ipsen Pharmaceuticals as a turn-key Neurology business. From the beginning of her career through 2003, Ms. McBrinn held numerous positions of increasing responsibility in sales and marketing management at Pfizer, including positions as Global and US VP of Marketing launching and growing blockbuster and specialty products. Ms. McBrinn has significant experience in the commercialization and launch of biotech and pharmaceutical products, team building, strategic planning and general management. 
Ms. McBrinn earned her undergraduate degree in Biology from DeSales University and holds an MBA in Marketing from Widener University.